Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New outlook and dose association study (EPAMINONDAS)

Felicita Andreotti, Luciano Agati, Elena Conti, Eleonora Santucci, Teresa Rio, Federica Tarantino, Luigi Natale, Daniele Berardi, Antonella Mattatelli, Beatrice Musumeci, Lorenzo Bonomo, Massimo Volpe, Filippo Crea, Camillo Autore

Research output: Contribution to journalArticlepeer-review

Abstract

Erythropoietin (Epo) is a hematopoietic hormone produced mainly by the kidneys in response to hypoxia. Recent acquisitions in the fields of hematology, neurology, cardiology, and experimental medicine show cytoprotective, angiogenetic and antinflammatory effects of Epo. Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS, EudraCTno. 200500485386) is one of four ongoing randomized controlled trials, each testing the effects of Epo in >100 patients with STEMI. EPAMINONDAS is a multicenter, prospective, double-blind, placebo-controlled, dose-finding study assessing intravenous moderate doses of human recombinant Epo (epoietin-α, 100 or 200 IU/kg/die) versus placebo, given on the first 3 days, in 102 patients with first ST-segment elevation myocardial infarction. Initial dosing is within 12 h of primary percutaneous coronary revascularization. The primary endpoint is infarct size, quantified by CK-MB time-concentration curve, left ventricular wall motion score index, and pattern of contrast-enhanced magnetic resonance imaging. Secondary endpoints are ischemic recurrences, ventricular remodelling, and safety events, assessed in-hospital and at 12 months' follow-up. The results of current phase II studies will help define the safety/efficacy profile of Epo for patients with STEMI.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume28
Issue number4
DOIs
Publication statusPublished - 2009

Keywords

  • Human recombinant erythropoietin
  • Infarct size
  • Primary PCI
  • ST-segment elevation myocardial infarction

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New outlook and dose association study (EPAMINONDAS)'. Together they form a unique fingerprint.

Cite this